U.S. Major Depressive Disorder (MDD) Market: Industry Analysis & Outlook (2018-2022)
Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person’s ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.
MDD is the most common mental disorder in the U.S. Approximately 16 million American adults suffer from the major depressive disorder and about one-third of the MDD patient remain untreated. The number of treated patients is projected to rise on account of better medical access and rising awareness regarding depression. There are few potential drugs in development that are being developed with improved efficacy and safety for the treatment of MDD and are expected to contribute significantly to the market growth in the U.S.
The U.S. MDD market is expected to grow in future due to rising aging population, growing MDD prevalence, growing female prevalence, increasing prescription drugs spending, high unmet needs, and escalating mental health expenditure. Key trends of this market include rising number of mental health programs, increasing awareness, rapid drugs in development and direct to customer advertising. However, there are some factors which can hinder the growth of the market which includes patent expiry of drugs, stringent regulations, side effects associated with antidepressants and availability of alternative therapies.
The report “U.S. Major Depressive Disorder (MDD) Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. market. The report profiles the key players in the market including. Pfizer Inc., AstraZeneca, Eli Lily and Company and Lundbeck.
MDD is the most common mental disorder in the U.S. Approximately 16 million American adults suffer from the major depressive disorder and about one-third of the MDD patient remain untreated. The number of treated patients is projected to rise on account of better medical access and rising awareness regarding depression. There are few potential drugs in development that are being developed with improved efficacy and safety for the treatment of MDD and are expected to contribute significantly to the market growth in the U.S.
The U.S. MDD market is expected to grow in future due to rising aging population, growing MDD prevalence, growing female prevalence, increasing prescription drugs spending, high unmet needs, and escalating mental health expenditure. Key trends of this market include rising number of mental health programs, increasing awareness, rapid drugs in development and direct to customer advertising. However, there are some factors which can hinder the growth of the market which includes patent expiry of drugs, stringent regulations, side effects associated with antidepressants and availability of alternative therapies.
The report “U.S. Major Depressive Disorder (MDD) Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. market. The report profiles the key players in the market including. Pfizer Inc., AstraZeneca, Eli Lily and Company and Lundbeck.
1. MARKET OVERVIEW
1.1 Introduction
1.2 Causes of MDD
1.3 Symptoms of MDD
1.4 Diagnosis & Treatment of MDD
2. THE U.S. MDD MARKET
2.1 The U.S. MDD Market by Value
2.2 The U.S. MDD Market by Drug Type
2.3 The U.S. Anti-Depressants Drugs Market
2.4 The U.S. Antipsychotics Drugs Market
2.5 The U.S. Top Psychiatric Drugs Revenue
2.6 The U.S. MDD Prevalence Forecast by Age
2.7 The U.S. MDD Patient Population Forecast
2.8 The U.S. MDD Treated Patient Population Forecast
2.9 The U.S. MDD Patient Treatment
2.10 The U.S. MDD Patient Population with TMS Criteria
2.11 The U.S. MDD Patient Share by Symptoms
3. MARKET DYNAMICS
3.1 Growth Drivers
3.1.1 Growing Aging Population
3.1.2 Rising Female Population
3.1.3 Increasing Spending on Prescription Drugs
3.1.4 Increasing Prevalence of Depression
3.1.5 Growing Mental Health Expenditure
3.1.6 Unmet Need
3.2 Key Trends & Developments
3.2.1 Increasing Awareness for Depression
3.2.2 Direct to Customer Advertising
3.2.3 Rapid Acting Drugs In Development
3.2.4 Rising Number of Mental Health Programs
3.3 Challenges
3.3.1 Stringent Drug Regulations
3.3.2 Patent Expiry of Drugs
3.3.3 Complications and Side Effects associated with Anti-depressants
3.3.4 Availability of Other Therapies such as Meditation and Psychotherapy
4. COMPETITIVE LANDSCAPE
4.1 Global MDD Market
4.1.1 Revenue Comparison of Top Companies
4.1.2 Market Capitalization Comparison of Top Companies
4.1.3 Research & Development Expenditure Comparison of Top Companies
4.2 The U.S. MDD Market
4.2.1 The U.S. Anti-Depressants Market Comparison by Product Profile
4.2.2 The U.S. Anti-Psychotics Market Comparison by Product Profile
5. COMPANY PROFILES
5.1 Pfizer, Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
5.2 Eli Lilly and Company
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
5.3 AstraZeneca
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
5.4 Lundbeck
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
1.1 Introduction
1.2 Causes of MDD
1.3 Symptoms of MDD
1.4 Diagnosis & Treatment of MDD
2. THE U.S. MDD MARKET
2.1 The U.S. MDD Market by Value
2.2 The U.S. MDD Market by Drug Type
2.3 The U.S. Anti-Depressants Drugs Market
2.4 The U.S. Antipsychotics Drugs Market
2.5 The U.S. Top Psychiatric Drugs Revenue
2.6 The U.S. MDD Prevalence Forecast by Age
2.7 The U.S. MDD Patient Population Forecast
2.8 The U.S. MDD Treated Patient Population Forecast
2.9 The U.S. MDD Patient Treatment
2.10 The U.S. MDD Patient Population with TMS Criteria
2.11 The U.S. MDD Patient Share by Symptoms
3. MARKET DYNAMICS
3.1 Growth Drivers
3.1.1 Growing Aging Population
3.1.2 Rising Female Population
3.1.3 Increasing Spending on Prescription Drugs
3.1.4 Increasing Prevalence of Depression
3.1.5 Growing Mental Health Expenditure
3.1.6 Unmet Need
3.2 Key Trends & Developments
3.2.1 Increasing Awareness for Depression
3.2.2 Direct to Customer Advertising
3.2.3 Rapid Acting Drugs In Development
3.2.4 Rising Number of Mental Health Programs
3.3 Challenges
3.3.1 Stringent Drug Regulations
3.3.2 Patent Expiry of Drugs
3.3.3 Complications and Side Effects associated with Anti-depressants
3.3.4 Availability of Other Therapies such as Meditation and Psychotherapy
4. COMPETITIVE LANDSCAPE
4.1 Global MDD Market
4.1.1 Revenue Comparison of Top Companies
4.1.2 Market Capitalization Comparison of Top Companies
4.1.3 Research & Development Expenditure Comparison of Top Companies
4.2 The U.S. MDD Market
4.2.1 The U.S. Anti-Depressants Market Comparison by Product Profile
4.2.2 The U.S. Anti-Psychotics Market Comparison by Product Profile
5. COMPANY PROFILES
5.1 Pfizer, Inc.
5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
5.2 Eli Lilly and Company
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
5.3 AstraZeneca
5.3.1 Business Overview
5.3.2 Financial Overview
5.3.3 Business Strategies
5.4 Lundbeck
5.4.1 Business Overview
5.4.2 Financial Overview
5.4.3 Business Strategies
LIST OF FIGURES
Types of Depression
Causes & Symptoms of Depression
The U.S. MDD Market by Value (2017-2022)
The U.S. MDD Market by Drug Type (2017)
The U.S. Anti-Depressants Drugs Market (2017-2022)
The U.S. Antipsychotics Drugs Market (2017-2022)
The U.S. Top Psychiatric Drugs Revenue (2016)
The U.S. MDD Prevalence Forecast by Age (2017-2022)
The U.S. MDD Patient Population Forecast (2017-2022)
The U.S. MDD Treated Patient Population Forecast (2017-2022)
The U.S. MDD Patient Treatment (2017)
The U.S. MDD Patient Population with TMS Criteria (2017-2022)
The U.S. MDD Patient Share by Symptoms (2017)
The U.S. Aging Population (2013-2017)
Female Population in the U.S. (2013-2017)
Prescription Drug Spending in the U.S. (2013-2017)
Percentage of U.S. Youth with MDD by Gender (2013-2017)
The U.S. Mental Health Expenditure Forecast (2017-2022)
Side Effects of Anti-Depressant Drugs
Revenue Comparison of Top Companies (2017)
Market Capitalization Comparison of Top Companies (2017)
Research & Development Expenditure of Top Companies (2017)
Pfizer Inc. Revenue by Segment (2017)
Types of Depression
Causes & Symptoms of Depression
The U.S. MDD Market by Value (2017-2022)
The U.S. MDD Market by Drug Type (2017)
The U.S. Anti-Depressants Drugs Market (2017-2022)
The U.S. Antipsychotics Drugs Market (2017-2022)
The U.S. Top Psychiatric Drugs Revenue (2016)
The U.S. MDD Prevalence Forecast by Age (2017-2022)
The U.S. MDD Patient Population Forecast (2017-2022)
The U.S. MDD Treated Patient Population Forecast (2017-2022)
The U.S. MDD Patient Treatment (2017)
The U.S. MDD Patient Population with TMS Criteria (2017-2022)
The U.S. MDD Patient Share by Symptoms (2017)
The U.S. Aging Population (2013-2017)
Female Population in the U.S. (2013-2017)
Prescription Drug Spending in the U.S. (2013-2017)
Percentage of U.S. Youth with MDD by Gender (2013-2017)
The U.S. Mental Health Expenditure Forecast (2017-2022)
Side Effects of Anti-Depressant Drugs
Revenue Comparison of Top Companies (2017)
Market Capitalization Comparison of Top Companies (2017)
Research & Development Expenditure of Top Companies (2017)
Pfizer Inc. Revenue by Segment (2017)
LIST OF TABLES
Drug Pipeline for Treatment of MDD in the U.S.
The U.S. Anti-Depressants Market Comparison by Product Profile (2017)
The U.S. Anti-Psychotics Market Comparison by Product Profile (2017)
Pfizer Inc. Revenue and Net Income (2013-2017)
Pfizer Inc. R&D Expenditure (2015-2017)
Eli Lilly and Company Revenue by Segments (2017)
Eli Lilly and Company Revenue and Net Income (2013-2017)
Eli Lilly and Company Research and Development Expenditure (2015-2017)
AstraZeneca Revenue by Segments (2017)
AstraZeneca Revenue and Net Profit (2013-2017)
Lundbeck Revenue by Products (2017)
Lundbeck Revenue and Net Profit (2013-2017)
Lundbeck Research and Development Expenditure (2015-2017)
Drug Pipeline for Treatment of MDD in the U.S.
The U.S. Anti-Depressants Market Comparison by Product Profile (2017)
The U.S. Anti-Psychotics Market Comparison by Product Profile (2017)
Pfizer Inc. Revenue and Net Income (2013-2017)
Pfizer Inc. R&D Expenditure (2015-2017)
Eli Lilly and Company Revenue by Segments (2017)
Eli Lilly and Company Revenue and Net Income (2013-2017)
Eli Lilly and Company Research and Development Expenditure (2015-2017)
AstraZeneca Revenue by Segments (2017)
AstraZeneca Revenue and Net Profit (2013-2017)
Lundbeck Revenue by Products (2017)
Lundbeck Revenue and Net Profit (2013-2017)
Lundbeck Research and Development Expenditure (2015-2017)
